Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Pharmacovigilance PRR/ROR× | Kipimo cha Upenyezaji wa Seli za Caco-2× | |
|---|---|---|
| Nyanja | Famakolojia | Famakolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 2002 | 1989 |
| Mwanzilishi≠ | Arne Melander and colleagues | Ingrid Hidalgo |
| Aina≠ | safety signal detection | absorption screening |
| Chanzo asilia≠ | Szarfman, A., Tonning, J. M., Doraiswamy, P. M., & Osgood, D. J. (2002). Pharmacovigilance in the post-marketing setting: establishing causal links between drugs and adverse events. Drug Safety, 25(9), 619-631. link ↗ | Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749. DOI ↗ |
| Majina mbadala≠ | PRR, ROR, signal detection, adverse event monitoring | Caco-2 assay, intestinal permeability, ADME screening |
| Zinazohusiana | 3 | 3 |
| Muhtasari≠ | Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) are statistical methods for detecting safety signals in spontaneous adverse event reporting databases. Developed and formalized by researchers in the early 2000s, these measures identify drug-adverse event associations that warrant further investigation. | The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport. |
| ScholarGateSeti ya data ↗ |
|
|